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The CD4 T-cell count at the start of anti-
retroviral therapy (ART) is a critical indi-
cator in measuring how well programs
are responding to human immunodeﬁci-
ency virus (HIV). CD4 cell count measures
at initiation of ART are strongly associat-
ed with morbidity, mortality, life expec-
tancy, and program costs [1–5].
The ﬁrst programs to start providing
ART in sub-Saharan Africa were initially
confronted with very sick populations:
the median CD4 cell count at start of ART
in these early programs was <50 cells/µL
[6]. As HIV testing and program reach
expanded, the CD4 count at initiation of
ART increased to around 150 cells/µL by
2006–2007 [6, 7]. Since then, guidelines
have evolved toward recommending
ART initiation at higher CD4 counts [8],
and this has been associated with further
increases in CD4 at start of ART [9].
The expectation is that as guidelines
change and program coverage improves,
most patients will present to care and
start ART earlier, and this will result in
reductions in mortality, morbidity, and
costs. Put simply, the job will be become
progressively simpler as initial efforts to
expand access are rewarded by a patient
population that is increasingly asymp-
tomatic, requiring fewer clinic resources
and fewer clinical visits.
The ﬁndings of a systematic review and
meta-analysis of trends in CD4 at presen-
tation and ART initiation in sub-Saharan
Africa, by Siedner et al, published in this
issue of Clinical Infectious Diseases may
therefore come as a disappointment.
This systematic review assembled a large
meta-analytic dataset of studies reporting
CD4 at presentation or at start of ART in
sub-Saharan Africa and, surprisingly,
found no evidence of change between
2002 and 2013 [10]. However, it would
be wrong to take the ﬁndings as meaning
that no progress has been made. Meta-
analysis of published, aggregate data is
not the ideal approach to analyzing trends
in CD4 cell counts. In particular, such
analyses will be prone to ecological bias,
where misleading conclusions about indi-
viduals are derived from aggregate-level
data [11]. For example, the authors in-
cluded published data from 2 ART pro-
grams in Côte d’Ivoire and Malawi,
which participate in the International
Epidemiological Databases to Evaluate
AIDS (IeDEA) [12]. They used the medi-
an CD4 count of 128 cells/µL reported in
the publication [3] and assigned this
value to the median of the study period
(2005). These aggregated data were then
included in the meta-regression analysis,
which found no change in the CD4 count
at start of ART. However, the data from
these programs show that CD4 count in
fact increased by about 10 cells per year
from 2004 to 2007.
The way in which ecologic bias (also
known as the ecological fallacy, aggrega-
tion bias, or cross-level bias) can inﬂu-
ence analyses of CD4 cell count at
initiation is illustrated in Figure 1. The
black bubbles and the broken line repre-
sent the meta-regression of the data ag-
gregated at the program level: no trend
over time in CD4 counts is seen. The
red lines show that the aggregated data
hide the fact that in most ART programs
the CD4 cell count increased, with the
rate of increase differing between sites.
In support of this interpretation, among
the largest cohort studies (>10 000 pa-
tients) included in the meta-analysis that
provide information on CD4 change over
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time, all but 1 [13] report either calendar
year increases in median CD4 cell count
[14–17], reductions in the proportion of
patients presenting with low CD4 cell
counts [18], or both [19, 20]; these 7 stud-
ies account for around two-thirds (65%)
of the data included in the meta-analysis.
Furthermore, 2 recent analyses of large co-
hort collaborations reported improve-
ments in immune status at the start of
ART, for both adults [21] and children
[22]. The analysis in adults was based on
individual-level data from almost 400 000
patients and showed that in low- and mid-
dle-income countries the increase was
from about 90 cells/µL in 2002 to about
150 cells/µL in 2009 [21]. The annual in-
crease variedwithin country incomegroups
and was greater among women than men.
For example, among lower middle-income
countries, the annual change in median
CD4 cell counts ranged from –2 cells/µL
among Nigerian men to 13 cells/µL among
women in Côte d’Ivoire [21]. More recent
data from the IeDEA collaborative cohort
from 2013 show that among the 19 coun-
tries from sub-Saharan Africa, the median
CD4 count at the start of ART was >200
cells/µL in 17 countries, >250 cells/µL,
in 9 countries, and >300 cells/µL in 2 coun-
tries [23].
In light of these data, an appropriate
conclusion to draw from the available data
is that there have been program-level
increases in CD4 at start of ART over
time in most but not all programs, and
that the magnitude of this increase has
been variable. This ﬁnding is consistent
with operational research demonstrating
that some clinics and programs function
better than others. Reasons for this in-
clude human resource constraints, geo-
graphic differences in distance to services,
and differing engagement strategies [21].
Thus, although progress has been
made, the ﬁndings of all the studies
draw attention to the fact that the CD4
cell count at start of ART initiation in
sub-Saharan Africa remains far too low.
The current consensus deﬁnitions of
late presenters in Europe—a CD4 cell
count of <350 cells/µL or an AIDS diag-
nosis within 6 months of HIV diagnosis
—is associated with a >13-fold increased
risk of AIDS or death [24]. According to
this deﬁnition, even the latest estimates
for 2013 indicate that the majority of pa-
tients starting ART in sub-Saharan Africa
are late presenters.
The meta-analysis [10] also highlights
important declines in CD4 status around
100 cells/mm3 between engagement in
care and initiation of treatment, despite
the fact that average CD4 at engagement
in care warrants immediate initiation of
ART.A 100 cell/mm3 difference represents
a period of approximately one year, a pe-
riod of depletion linked to both decreased
future life expectancy and increased risk
of transmission. There are important
issues that need to be evaluated between
engagement in care and initiation of
ART, such as management of coinfec-
tions to reduce the likelihood of immune
response inﬂammatory syndrome and
patient readiness.
In conclusion, to further reduce HIV-
associated illness and death, a major focus
of attention is needed on increasing CD4
at entry to care. As the authors of the sys-
tematic review and meta-analysis rightly
conclude, renewed efforts are needed to
improve the timeliness of ART initiation,
including through earlier HIV testing and
referral. Community-based testing ap-
proaches that include house-to-house
testing [25], point-of-care CD4 testing,
and peer support [26] are among the in-
terventions that could help raise the base-
line. With almost 12 million people now
on ART in low- and middle-income set-
tings, emphasis is shifting toward adapt-
ing service delivery models to support the
management of HIV as a lifelong chronic
disease. This requires decentralizing care
such that healthier patients require less
clinical investment. Although this is cer-
tainly needed and appropriate for those
on ART, programs need to retain clinical
capacity to respond to late presenters as a
critical component of the AIDS response.
Finally, monitoring of CD4 cell counts at
presentation and start of ART in sub-
Saharan Africa and elsewhere should be
based on individual-level data, rather
than aggregate data.
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